Two new groundbreaking drugs could slow the memory impairment, thinking skills and overall brain decline — and both are ...

"These results are stunning." The post Scientists Identify Possible Game Changing Treatment for Alzheimer’s Disease That ...

A breakthrough new Alzheimer’s disease treatment is stopping neurodegeneration in its tracks, even before symptoms appear.

"Neumora’s Alzheimer’s disease agitation drug shows early success in Phase Ib trial" was originally created and published by ...

Activating two somatostatin receptors enhances amyloid beta breakdown and improves memory in models of Alzheimer’s disease.

Age remains the greatest risk factor for Alzheimer's. However, research has shown that early-onset of the disease has also ...

A new compound has been shown to reverse late stage Alzheimer's disease in lab mice, which gives millions of sufferers new ...

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's ...

The sNDA for AXS-05 for Alzheimer disease agitation includes findings from four phase 3 trials showing improved behaviors and delayed relapse.

The impact of Alzheimer’s Disease touches nearly all of us in some way. According to the Alzheimer’s Association, 1 in 9 Americans over 65 is afflicted with the disease. November is Alzheimer’s ...

University of Toronto provides funding as a founding partner of The Conversation CA. University of Toronto provides funding as a member of The Conversation CA-FR. Why are researchers still fumbling in ...

Largest donation in the non-profit organization's 20-year history WELLESLEY HILLS, Mass., Sept. 26, 2025 /PRNewswire/ -- Today, Cure Alzheimer's Fund (CureAlz) announced it has received a $50 million ...